Company intelligence / Profile preview

Next Gen Diagnostics

West Palm Beach, Florida, United Statesnextgen-dx.com ↗

Ownership: Private
Employees: ~24
Development stage: Commercial

Overview

Next Gen Diagnostics has developed a highly automated, end-to-end workflow for whole-genome sequencing of bacterial pathogens. Their system enables rapid detection of infection transmission events and antimicrobial resistance with high throughput, low cost, and fast turnaround. The platform is validated through collaborations with leading academic groups in the US, Europe, and Israel. Clinical deployment into hospitals is planned for early 2025.

Therapeutic areas: Infectious Diseases
Modalities: DeviceBioinformatics platformSequencing-based diagnostics
Industry: Molecular Diagnostics

Partnerships

Standard BioTools (collaborated on the NGD100 microfluidic instrument)

Beyond the preview

Go deeper on Next Gen Diagnostics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Next Gen Diagnostics.

Explore the full profile